ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025

Rhea-AI Summary

ADMA Biologics (Nasdaq: ADMA), a U.S.-based commercial biopharmaceutical company focused on specialty biologics, has scheduled its first quarter 2025 financial results announcement for May 7, 2025, after U.S. market close.

The company will host a live conference call and audio webcast at 4:30 p.m. ET on the same day. Participants must pre-register to receive dial-in numbers and a unique PIN, with recommended joining time being 10 minutes before the event start.

Two participation options are available:

• Interactive Q&A: Register to receive dial-in details and PIN
• Listen-only: Access the live webcast directly

An archived replay will be accessible in the investor section of ADMA's website under "Events & Webcasts."

Conference Call Scheduled for May 7, 2025, at 4:30 p.m. ET

RAMSEY, N.J. and BOCA RATON, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report first quarter 2025 financial results on May 7, 2025, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.

To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and unique PIN. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast here. An archived replay of the event will be available located under “Events & Webcasts” in the investor section of the Company’s website at https://ir.admabiologics.com/events-webcasts.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Additionally, ADMA is developing SG-001, a pre-clinical, investigative hyperimmune globulin targeting S. pneumonia. ADMA manufactures its immune globulin products and product candidates at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

INVESTOR RELATIONS CONTACT:
Argot Partners | 212-600-1902 | ADMA@argotpartners.com

FAQ

When will ADMA Biologics (ADMA) release Q1 2025 earnings?

ADMA Biologics will release its first quarter 2025 financial results on May 7, 2025, after U.S. financial markets close.

How can investors join ADMA Biologics Q1 2025 earnings call?

Investors can join ADMA's earnings call on May 7, 2025, at 4:30 p.m. ET by registering online to receive dial-in numbers and a unique PIN. It's recommended to join 10 minutes before the start.

Where can I listen to ADMA Biologics Q1 2025 earnings webcast?

The live webcast can be accessed through ADMA's investor relations website at https://ir.admabiologics.com/events-webcasts, where an archived replay will also be available.

What time is ADMA Biologics earnings call on May 7, 2025?

ADMA Biologics' earnings conference call and audio webcast is scheduled for 4:30 p.m. ET on May 7, 2025.

Can I access ADMA Biologics Q1 2025 earnings call replay?

Yes, an archived replay of the earnings call will be available in the 'Events & Webcasts' section of ADMA's investor relations website.